Kezar Life Sciences Inc

+0.06 (+1.09%)
Earnings Announcements

Kezar Reports Q4 And Year-End 2021 Financial Results

Published: 03/17/2022 20:08 GMT
Kezar Life Sciences Inc (KZR) - Kezar Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Update.
Q4 Loss per Share $0.25.
Cash, Cash Equivalents and Marketable Securities Totaled $208.4 Million As of Year-end 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.29

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.32

More details on our Analysts Page.